Neulasta and neupogen have similar efficacy for raising the number of neutrophils in the body. However, they are given in different ways.
|Cost||$$$$ Thousands||$$ Hundreds|
|Mechanism of action||Colony stimulating factor that stimulates production and activation of neutrophils||Colony stimulating factor|
|Why is it given?||Prevention of chemotherapy-induced neutropenia||Prevention of chemotherapy-induced neutropenia
*Prevention of induction chemotherapy-induced neutropenia in AML, in the setting of bone marrow transplant, and mobilizer for peripheral progenitor blood cell harvesting
|How long does it last for?||Half life=15-80 hours (the “Peg-“ recombinant component makes it last longer)||Half life=3-5 hours|
|How is it given?||Subcutaneous injection >24 hours after last chemotherapy cycle given ONCE||IV infusion or subcutaneous injection given daily to reach target ANC|
|Adverse effects||Achy muscle or bone pain (ostealgia), rarely capillary leak syndrome, ARDS, glomerulonephritis, hypersensitivity reactions, inducing sickle cell crisis||Also ostealgia, many of the other same adverse effect reported, fever, thrombocytopenia|